Pancragen (KEDW): 20mg

Description

Pancragen is a synthetic tetrapeptide (lys-glu-asp-trp, kedw) from the khavinson bioregulator programme — a series of short, organ-specific peptides developed at the st. petersburg institute of bioregulation and gerontology. pancragen is the pancreas-targeting member of this family, derived from sequences originally isolated from bovine pancreatic tissue. the proposed mechanism involves selective binding to pancreatic cell chromatin, modulating gene expression in both endocrine islet cells (insulin-producing beta cells) and exocrine acinar cells. in cell culture studies, pancragen stimulated expression of pancreatic differentiation factors — including cxcl12 and hoxa3 — particularly in aged cells, suggesting a role in restoring youthful gene expression patterns in senescent pancreatic tissue. published evidence is limited and concentrated within the khavinson research group. a study in aged cynomolgus monkeys (siakkou et al., adv gerontol, ~2012) examined the compound's effect on pancreatic endocrine function and found improvements in insulin secretion markers. a small human study in 63 elderly patients with type 2 diabetes observed improvements in fasting glucose and beta-cell functional indices over a 20-day course. no large-scale, independently replicated western rcts exist. evidence is preclinical and early-phase. for research and educational purposes only. not fda-approved for any indication. consult a qualified healthcare professional.

Specifications

Dose Calculator